1
|
Stammler R, Ta VA, Cohen E, Ram-Wolff C, Bozonnat A, Battesti G, Louveau B, Mourah S, Battistella M, Moins-Teisserenc H, de Masson A. Failure of second challenge with mogamulizumab in C-C chemokine receptor 4-positive cutaneous T-cell lymphoma. Br J Dermatol 2024; 190:920-921. [PMID: 38390970 DOI: 10.1093/bjd/ljae085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 02/02/2024] [Accepted: 02/29/2024] [Indexed: 02/24/2024]
Abstract
We report three patients with Sézary syndrome who had previously been successfully treated with mogamulizumab and then failed a second course of the same treatment, despite positive CCR4 expression at the second initiation of mogamulizumab. This suggests that secondary resistance of blood disease to mogamulizumab may be independent of target expression.
Collapse
Affiliation(s)
| | - Van Anh Ta
- INSERM U1160, Institut de Recherche Saint-Louis
- Université Paris Cité, Paris, France
| | | | | | - Alizée Bozonnat
- Department of Dermatology
- INSERM U976
- Université Paris Cité, Paris, France
| | - Gilles Battesti
- Department of Dermatology
- INSERM U976
- Université Paris Cité, Paris, France
| | - Baptiste Louveau
- INSERM U976
- Université Paris Cité, Paris, France
- Department of Pharmacogenomics and Tumor Genomics
| | - Samia Mourah
- INSERM U976
- Université Paris Cité, Paris, France
- Department of Pharmacogenomics and Tumor Genomics
| | | | - Hélène Moins-Teisserenc
- INSERM U1160, Institut de Recherche Saint-Louis
- Université Paris Cité, Paris, France
- Haematology Laboratory, Saint Louis Hospital, AP-HP
| | - Adèle de Masson
- Department of Dermatology
- INSERM U976
- Université Paris Cité, Paris, France
| |
Collapse
|
2
|
Tzoumpa S, Ingen-Housz-Oro S, de Masson A, Pham-Ledard A, El Aarbaoui T, Dereure O, Quereux G, Faiz S, de Vicq de Cumptich M, Ram-Wolff C, Janela-Lapert R, Guenova E, Lheure C, Le Corre Y, Adamski H, Blanchard M, Bonnet N, Amatore F, Grange F, Troin L, Bagot M, Beylot-Barry M. Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study). Br J Dermatol 2024:ljae153. [PMID: 38660811 DOI: 10.1093/bjd/ljae153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Revised: 03/30/2024] [Accepted: 04/24/2024] [Indexed: 04/26/2024]
Abstract
The results of this study suggest that a progressive discontinuation of mogamulizumab should be considered once response is obtained in Sezary syndrome patients, even after a treatment of short-duration. This may possibly minimize the risk of adverse effects, costs, and resistance to mogamulizumab. Additionally, our study emphasizes that mogamulizumab rechallenge should be encouraged as first-choice for relapsing patients.
Collapse
Affiliation(s)
- Sofia Tzoumpa
- Department of Dermatology, Henri-Mondor University Hospital, AP-HP , Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri-Mondor University Hospital, AP-HP , Créteil, France
- Paris Est Créteil University, EpiDermE, Créteil, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Adèle de Masson
- Department of Dermatology, Saint-Louis University Hospital, AP-HP, Université Paris Cité, Paris, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Anne Pham-Ledard
- Department of Dermatology, INSERM 1312, Bordeaux University Hospital, Bordeaux, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | | | - Olivier Dereure
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Gaëlle Quereux
- Department of Dermatology, CHU Nantes, Nantes University, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Sarah Faiz
- Department of Dermatology, Lille University Hospital, Lille, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Marine de Vicq de Cumptich
- Department of Dermatology, Saint-Pierre, Brugmann University Hospitals, Brussels, Belgium and Department of Hematology Bordet Institute, Brussels, Belgium
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis University Hospital, AP-HP, Université Paris Cité, Paris, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Raphaël Janela-Lapert
- Department of Dermatology, Rouen University Hospital, Rouen, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Emmanuella Guenova
- Department of Dermatology, Lausanne University Hospital, and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Coralie Lheure
- Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Yannick Le Corre
- Department of Dermatology, Angers University Hospital, Angers, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Henri Adamski
- Department of Dermatology, Rennes University Hospital, Rennes, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Maël Blanchard
- Department of Dermatology, Lausanne University Hospital, and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
- Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Nathalie Bonnet
- Department of Dermatology, Hôpital Nord, AP-HM, Marseille, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Florent Amatore
- Department of Dermatology, Hôpital Nord, AP-HM, Marseille, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Florent Grange
- Department of Dermatology, Centre Hospitalier de Valence, Valence, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Laura Troin
- Department of Dermatology, Nice University Hospital, Nice, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis University Hospital, AP-HP, Université Paris Cité, Paris, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Marie Beylot-Barry
- Department of Dermatology, INSERM 1312, Bordeaux University Hospital, Bordeaux, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| |
Collapse
|
3
|
Mitsunaga K, Bagot M, Ram-Wolff C, Guenova E, von Gugelberg C, Hodak E, Amitay-Laish I, Papadavid E, Jonak C, Porkert S, Scarisbrick J, Applewaite R, Beylot-Barry M, Nicolay J, Quaglino P, Sanches JA, Cury-Martins J, Lora-Pablos D, Ortiz P. Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides/Sézary syndrome using Time to Next Treatment as a measure of clinical benefit: An EORTC CLTG study. Br J Dermatol 2024:ljae152. [PMID: 38596857 DOI: 10.1093/bjd/ljae152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Revised: 04/03/2024] [Accepted: 04/08/2024] [Indexed: 04/11/2024]
Abstract
INTRODUCTION Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic malignant diseases that typically necessitate diverse strategies to achieve remission. Systemic interferon alpha (IFN-α, subtypes 2a and 2b) has been used for MF/SS since 1984, however its production was recently stopped and so the recombinant pegylated (PEG) form of IFN α-2a remains as single IFN alternative treatment, even though not approved for MF/SS. OBJECTIVE To assess effectiveness and safety of PEG IFN α-2a in monotherapy and in combination with other treatments using time to next treatment (TTNT) as a measure of clinical therapeutic benefit in real world setting. METHODS We conducted an international and multicenter retrospective study of patients with MF and SS at any stage, treated with PEG IFN α-2a, from July 2012 to February 2022. Patients were included across 11 centers in 10 countries. Primary endpoints were to determine TTNT of PEG IFN α-2a and the adverse events (AE) in MF/SS. RESULTS In total 105 patients were included, mean age was 61 (22-86 years); 42 (40%) with disease stage IA-IIA, 63 (60%) with stage IIB-IVB. PEG IFN α-2a was combined with other therapies in 67 (64%) patients, usually with extracorporeal photopheresis (36%) and bexarotene (22%). Fifty-seven percent of stage I-IIA patients achieved ORR, whereas 51% of stage IIB-IVB. Combination therapy showed a TTNT of 10.4 months, while 7 months in monotherapy (p=0.0099). Overall, TTNT was 9.2 months, ORR was 53% (56/105), CR and PR were 13% and 40%, respectively.AE were described in 69% (72) of the patients. Flu-like symptoms (27%), lymphopenia (23%) and elevated liver function (10%) were the most frequently reported. Grade 3-4 adverse events were reported in 23 (21%) patients, which were mostly related to myelosuppression. LIMITATIONS retrospective data analysis and unrestricted number of combination therapies. CONCLUSIONS PEG IFN α-2a for MF/SS showed ORR of 53%, TTNT of 9.2 months, superiority of combination regimens in comparison to monotherapy and doses of 180 mcg/weekly related to higher ORR.
Collapse
Affiliation(s)
- Keila Mitsunaga
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Martine Bagot
- Department of Dermatology, Univerdité Paris Cité, Saint-Louis Hospital, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Univerdité Paris Cité, Saint-Louis Hospital, Paris, France
| | - Emmanuella Guenova
- Department of Dermatology, University Hospital Zurich and Faculty of Medicine, Zurich, Switzerland
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, Lausanne, Switzerland
| | - Christina von Gugelberg
- Department of Dermatology, University Hospital Zurich and Faculty of Medicine, Zurich, Switzerland
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, Lausanne, Switzerland
| | - Emmilia Hodak
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Iris Amitay-Laish
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Evangelia Papadavid
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - Constanze Jonak
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Stefanie Porkert
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Julia Scarisbrick
- University Hospitals of Birmingham (UHB), Birmingham, United Kingdom
| | - Rona Applewaite
- University Hospitals of Birmingham (UHB), Birmingham, United Kingdom
| | - Marie Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital Center, Bordeaux, France
| | - Jan Nicolay
- Department of Dermatology, Universitätsmedizin Mannheim, Mannheim, Germany
| | - Pietro Quaglino
- Department of Medical Science, University of Turin Medical School, Turin, Italy
| | | | | | - David Lora-Pablos
- Scientific Support Unit (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Pablo Ortiz
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
4
|
Giustiniani J, Ta VA, Belkhelouat S, Battistella M, Ouahbi D, Ram-Wolff C, Louveau B, Mourah S, Bagot M, Moins-Teisserenc H, Ortonne N, Bensussan A, De Masson A. Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas. J Invest Dermatol 2024:S0022-202X(24)00259-8. [PMID: 38555062 DOI: 10.1016/j.jid.2024.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 02/29/2024] [Accepted: 03/01/2024] [Indexed: 04/02/2024]
Affiliation(s)
- Jérôme Giustiniani
- INSERM U955, Institut Mondor de Recherche Biomédicale, Team Ortonne (Neurofibromatosis and lymphoma oncogenesis - NFL), Créteil, France; Université Paris Est Créteil, Créteil, France
| | - Van Anh Ta
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Sadjia Belkhelouat
- INSERM U955, Institut Mondor de Recherche Biomédicale, Team Ortonne (Neurofibromatosis and lymphoma oncogenesis - NFL), Créteil, France; Université Paris Est Créteil, Créteil, France
| | - Maxime Battistella
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Pathology Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Dina Ouahbi
- Department of Bioinformatics, Institut de Recherche Saint-Louis, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Baptiste Louveau
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Solid Tumor Genomics, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Samia Mourah
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Solid Tumor Genomics, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Martine Bagot
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Hélène Moins-Teisserenc
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France; Hematology Laboratory, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Nicolas Ortonne
- INSERM U955, Institut Mondor de Recherche Biomédicale, Team Ortonne (Neurofibromatosis and lymphoma oncogenesis - NFL), Créteil, France; Université Paris Est Créteil, Créteil, France; Department of Pathology, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Creteil, France
| | - Armand Bensussan
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Institut Jean Godinot, Reims, France; Mohammed VI Polytechnic University, Ben Guerir, Morocco
| | - Adèle De Masson
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.
| |
Collapse
|
5
|
Lazaridou I, Alqahtani M, Louveau B, Ram-Wolff C, Alharbi B, Al Hage J, Dumont M, Bouaziz JD, Bagot M, Moins-Teisserenc H, Rivet J, Battistella M, Mourah S, de Masson A. Impact of blood tumour clone frequency on time to next treatment in mycosis fungoides. J Eur Acad Dermatol Venereol 2024. [PMID: 38469982 DOI: 10.1111/jdv.19922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 02/13/2024] [Indexed: 03/13/2024]
Affiliation(s)
- Ingrid Lazaridou
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Mohammed Alqahtani
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
| | - Baptiste Louveau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis University Hospital, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
| | - Bader Alharbi
- King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia
| | - Jana Al Hage
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
| | - Maëlle Dumont
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
| | - Jean-David Bouaziz
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Hélène Moins-Teisserenc
- Université Paris Cité, Paris, France
- Hematology Laboratory, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U1160, Institute de Recherche Saint-Louis, Paris, France
| | - Jacqueline Rivet
- Department of Pathology, APHP, Saint-Louis University Hospital, Paris, France
| | - Maxime Battistella
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Department of Pathology, APHP, Saint-Louis University Hospital, Paris, France
| | - Samia Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis University Hospital, Paris, France
| | - Adèle de Masson
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
6
|
Cohen E, Bozonnat A, Battistella M, Calvani J, Vignon-Pennamen MD, Rivet J, Moins-Teisserenc H, Ta VA, Ram-Wolff C, Bouaziz JD, Mahevas T, Bagot M, Mourah S, Louveau B, Sicre de Fontbrune F, Peffault de Latour R, de Masson A, Battesti G. Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib. J Eur Acad Dermatol Venereol 2024; 38:e32-e34. [PMID: 37561935 DOI: 10.1111/jdv.19408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 08/03/2023] [Indexed: 08/12/2023]
Affiliation(s)
- Elisabeth Cohen
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | - Alizée Bozonnat
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
| | - Maxime Battistella
- Université Paris Cité, Paris, France
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Julien Calvani
- Université Paris Cité, Paris, France
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | | | - Jacqueline Rivet
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
| | - Hélène Moins-Teisserenc
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France
| | - Van-Anh Ta
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | | | - Jean-David Bouaziz
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Thibault Mahevas
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Samia Mourah
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Baptiste Louveau
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | | | | | - Adèle de Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Gilles Battesti
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
7
|
Campbell BA, Dobos G, Haider Z, Prince HM, Bagot M, Evison F, van der Weyden C, McCormack C, Ram-Wolff C, Miladi M, Scarisbrick JJ. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv 2023; 7:6639-6647. [PMID: 37648672 PMCID: PMC10628811 DOI: 10.1182/bloodadvances.2023011041] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 08/22/2023] [Accepted: 08/22/2023] [Indexed: 09/01/2023] Open
Abstract
Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study examines patterns of clinical care and therapeutic benefit as measured by TTNT. TTNT was calculated for monotherapies and combination therapies, with consideration to treatment line. 178 patients with SS (73% de novo, 27% secondary) were included, receiving 721 lines of systemic therapy, with median follow-up of 56.9 months. Across all lines, 58 different therapeutic regimens were prescribed (54 were systemic therapies) and classified into 17 treatment groups. The most common first-line treatments were extracorporeal photopheresis (ECP)-containing combination therapy (20%) and retinoid monotherapy (19%). Median TTNT for all first-line therapies was short (5.4 months). First-line, combination therapies had longer median TTNT than monotherapies, 10.0 vs 5.0 months (P = .004), respectively. Later delivery of combination therapies was associated with shorter clinical benefit, with median TTNT reduced to 6.2 and 2.2 months for mid-line (2nd-4th line) and late-line (≥5th line), respectively (P < .001). First-line ECP-containing treatments were associated with longer median TTNT than non-ECP-containing treatments, 9.0 vs 4.9 months (P = .007). For both ECP-monotherapy and ECP-containing combination therapy, significant reductions in TTNT were seen in later lines. These data suggest therapeutic benefit from first-line delivery of combination therapy for SS and favor early inclusion of ECP in the treatment algorithm for those who can access it.
Collapse
Affiliation(s)
- Belinda A. Campbell
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
- Department of Clinical Pathology, The University of Melbourne, Parkville, Australia
| | - Gabor Dobos
- Department of Dermatology, Hôpital Saint Louis, Université Paris Cité, Paris, France
- Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Zahra Haider
- Department of Dermatology, Queen Elizabeth Hospital, Birmingham, United Kingdom
| | - H. Miles Prince
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
- Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne Australia
| | - Martine Bagot
- Department of Dermatology, Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Felicity Evison
- Health Data Science Team, Research Development and Innovation, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Carrie van der Weyden
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
- Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne Australia
| | - Chris McCormack
- Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
- Department of Surgery, The University of Melbourne, Parkville, Australia
| | - Caroline Ram-Wolff
- Department of Dermatology, Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Maryam Miladi
- Department of Dermatology, Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Julia J Scarisbrick
- Department of Dermatology, University Hospital Birmingham, Birmingham, United Kingdom
| |
Collapse
|
8
|
Calugareanu A, de Masson A, Battistella M, Michel L, Ram-Wolff C, Bouaziz JD, Peltier S, Bensussan A, Bagot M, Dobos G. Exploring the Nonlymphocytic Cutaneous Microenvironment in Advanced Cutaneous T-Cell Lymphomas using Single-Cell RNA Sequencing. J Invest Dermatol 2023; 143:2078-2082.e4. [PMID: 37100194 DOI: 10.1016/j.jid.2022.07.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 06/29/2022] [Accepted: 07/23/2022] [Indexed: 04/28/2023]
Affiliation(s)
- Andreea Calugareanu
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Adèle de Masson
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Maxime Battistella
- UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France; Pathology Department, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France
| | - Laurence Michel
- UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France
| | - Jean-David Bouaziz
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Sandy Peltier
- UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Armand Bensussan
- UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Martine Bagot
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Gabor Dobos
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France; Department of Dermatology, Venereology, and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
| |
Collapse
|
9
|
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D'Incan M, Grange F, Braniste V, Bagot M. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37:1777-1784. [PMID: 37113040 DOI: 10.1111/jdv.19134] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 03/29/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T-cell lymphoma (CTCL): Sézary syndrome (SS) or Mycosis Fungoides (MF). OBJECTIVES The real-world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF). METHODS In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres. The overall response rate (ORR) under treatment was described (primary criterion), as well as treatment use and safety data. RESULTS The 122 analysed patients (69 SS, 53 MF) were aged 66.6 ± 12.1 years at mogamulizumab initiation, and their median disease duration was 2.5 years (IQR: 1.3-5.6). Prior to treatment start, they received a median of three systemic CTCL therapies (2-5). Overall, 77.8% of patients suffered from advanced disease (Stage IIB-IVB), with frequent blood (B1/B2) involvement (67.5%). Over the treatment period (median: 4.6 months, 2.1-7.2), 96.7% of patients received all the planned mogamulizumab infusions. Among the 109 patients evaluable for effectiveness, ORR was 58.7% (95% CI [48.9-68.1]) overall, 69.5% [56.1-80.8] in SS and 46.0% [31.8-60.7] in MF. Compartmental response in the blood was observed in 81.8% [69.1-90.9] of SS patients. Skin responses were observed in 57.0% [47.0-66.5] of patients overall, 66.7% [52.9-78.6] in SS and 46.0% [31.8-60.7] in MF. The most common serious adverse drug reactions were rash (8.1% of patients) and infusion-related reactions (2.4%) which led to treatment discontinuation in 7.3% and 0.8% of patients, respectively. One patient with SS died from mogamulizumab-related tumour lysis syndrome. CONCLUSIONS This large French study confirmed the effectiveness and tolerability of mogamulizumab in SS and MF patients in routine medical practice.
Collapse
Affiliation(s)
- M Beylot-Barry
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - G Quereux
- Dermatology Department, Nantes University Hospital, University of Nantes, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, Nantes, France
| | - C Nardin
- Dermatology Department, Minjoz Hospital, CHU Besancon, Besancon, France
- INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France
| | - A-B Duval-Modeste
- Department of Dermatology, INSERM U519, Rouen University Hospital, Rouen, France
| | - O Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - S Dalac-Rat
- Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
- Department of Dermatology, HTCC, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - A Pham-Ledard
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M D'Incan
- Dermatology and Cutaneous Oncology, Estaing University Hospital, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - F Grange
- Department of Dermatology, Valence Hospital, Valence, France
| | - V Braniste
- Kyowa Kirin Pharma, Medical Affairs, Neuilly-sur-Seine, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
10
|
Ranjbaryan M, Calvani J, Louveau B, Cuccuini W, Battesti G, Bozonnat A, Moins-Teisserenc H, Michonneau D, Bagot M, Ram-Wolff C, Dobos G, Mourah S, Battistella M, de Masson A. Graft-versus-lymphoma effect in skin after allogeneic hematopoietic stem cell transplantation for Sézary syndrome. Eur J Dermatol 2023; 33:439-440. [PMID: 37823502 DOI: 10.1684/ejd.2023.4522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/13/2023]
Affiliation(s)
- Merian Ranjbaryan
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Julien Calvani
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France, INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France
| | - Baptiste Louveau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France, Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Wendy Cuccuini
- Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France
| | - Gilles Battesti
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Alizée Bozonnat
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Hélène Moins-Teisserenc
- Université Paris Cité, France, Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France, INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | - David Michonneau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France, Department of Hematology and Bone Marrow Transplant, APHP, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France, INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France
| | | | - Gabor Dobos
- Department of Dermatology, Charité University Hospital, Berlin, Germany
| | - Samia Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France, Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Maxime Battistella
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France, INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France
| | - Adèle de Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France, INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France
| |
Collapse
|
11
|
Ta VA, Battistella M, Zhao LP, Dobos G, Ram-Wolff C, Madelaine I, Bories JC, Tournilhac O, Rouanet J, Veyrat-Masson R, Bouaziz JD, Marie-Cardine A, Bagot M, Bensussan A, Moins-Teisserenc H, De Masson A. CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas. J Invest Dermatol 2023; 143:1329-1332.e3. [PMID: 36716922 DOI: 10.1016/j.jid.2023.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Accepted: 01/09/2023] [Indexed: 01/30/2023]
Affiliation(s)
- Van Anh Ta
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France
| | - Maxime Battistella
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Pathology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France
| | - Lin Pierre Zhao
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France
| | - Gabor Dobos
- Department of Dermatology, Charité Hospital, Berlin, Germany
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Isabelle Madelaine
- Pharmacy, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Christophe Bories
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France
| | - Olivier Tournilhac
- Department of Hematology, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France
| | - Jacques Rouanet
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France
| | - Richard Veyrat-Masson
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France
| | - Jean-David Bouaziz
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Marie-Cardine
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France
| | - Martine Bagot
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Armand Bensussan
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France
| | - Hélène Moins-Teisserenc
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Adèle De Masson
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
| |
Collapse
|
12
|
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet 2023; 401:1941-1950. [PMID: 37105210 DOI: 10.1016/s0140-6736(23)00329-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 01/26/2023] [Accepted: 02/10/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs. METHODS In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy. Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sézary syndrome, and at least one poor prognostic criteria. Participants were excluded if they were not in complete or partial remission of the disease. Propensity score 1:1 matching with replacement (ie, that each participant treated with HSCT was matched to the participant with the closest propensity score treated with non-HSCT therapy, even if they had already been matched) was used to handle confounding factors, with the balance of covariate distribution between HSCT and non-HSCT groups assessed using standardised mean differences. The primary endpoint was progression-free survival in the matched intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02520908), and is currently active but not recruiting. FINDINGS From June 1, 2016, to March 3, 2022, total of 99 participants were enrolled at 17 centres in France. Participants with a sibling or matched unrelated donor were assigned to allogeneic HSCT (HSCT group, n=55 [56%]) and participants without a donor were assigned to non-allogeneic HSCT treatment (non-HSCT group, n=44 [44%]). The median follow-up among survivors was 12·6 months (IQR 11·0-35·2). In the HSCT group, 51 participants (93%) were 1:1 matched to participants from the non-HSCT group. In the intention-to-treat analysis, median progression-free survival was significantly longer in the HSCT group (9·0 months [95% CI 6·6-30·5]) than in the non-HSCT group (3·0 months [2·0-6·3]), with a hazard ratio of 0·38 (95% CI 0·21-0·69; p<0·0001). In the per-protocol population, 40 participants (78%) in the HSCT group had 101 serious events and 29 participants (67%) in the non-HSCT group had 70 serious adverse events. The most common serious adverse event other than graft-versus-host disease in both groups was infections, occurring in 30 participants (59%) in the HSCT group and in 19 participants (44%) in the non-HSCT group. INTERPRETATION Allogeneic HSCT was associated with significantly longer progression-free survival in participants with advanced-stage CTCLs. These results indicate that allogeneic HSCT treatment should be made available to individuals with high-risk, advanced-stage mycosis fungoides or Sézary syndrome who achieve pre-transplant disease remission. FUNDING French Ministry of Health, National Cancer Institute, Programme Hospitalier de Recherche Clinique en Cancérologie.
Collapse
Affiliation(s)
- Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.
| | - Marie Beylot-Barry
- Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Baptiste Mear
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Stéphane Dalle
- Department of Dermatology, Hôpital Lyon-Sud, Lyon, France
| | - Michel d'Incan
- Department of Dermatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France
| | - Corentin Orvain
- Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France; Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, Angers, France; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1307, Centre National de la Recherche Scientifique Unité Mixte de Recherche 6075, Nantes Université, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Université d'Angers, Angers, France
| | - Julie Abraham
- Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - Olivier Dereure
- Department of Dermatology and Institut National de la Santé et de la Recherche Médicale U1058 Pathogenesis and Control of Chronic and Emergent Infections, University of Montpellier, Montpellier, France
| | - Amandine Charbonnier
- Department of Hematology, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | - Jérôme Cornillon
- Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France
| | - Christine Longvert
- Department of Dermatology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Stéphane Barete
- Department of Dermatology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Serge Boulinguez
- Department of Dermatology, Centre Hospitalier Universitaire Toulouse, Toulouse, France
| | - Ewa Wierzbicka-Hainaut
- Department of Dermatology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - François Aubin
- Department of Dermatology, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Marie-Thérèse Rubio
- Department of Hematology, Hôpital Brabois, Centre Hospitalier Régional Universitaire Nancy, Nancy, France; Centre National de la Recherche Scientifique Unité Mixte de Recherche 7365, Ingéniérie Moléculaire et Physiopathologie Articulaire, Biopole, University of Lorraine, Nancy, France
| | - Marc Bernard
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Aline Schmidt-Tanguy
- Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Roch Houot
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France; Institut National de la Santé et de la Recherche Médicale U1236, Rennes, France
| | - Anne Pham-Ledard
- Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France
| | - David Michonneau
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Pauline Brice
- Department of Hemato-Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Jean-David Bouaziz
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Florent Grange
- Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | - Hélène Moins-Teisserenc
- Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France
| | - Katayoun Jondeau
- Department of Hematology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Laurence Michel
- Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Samia Mourah
- Department of Tumor Genomics and Pharmacology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Maxime Battistella
- Pathology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Etienne Daguindau
- Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Michael Loschi
- Department of Hematology, Hôpital L'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Alexandra Picard
- Department of Dermatology, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Nathalie Franck
- Department of Dermatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Natacha Maillard
- Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Anne Huynh
- Department of Hematology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | - Stéphanie Nguyen
- Department of Hematology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Ambroise Marçais
- Department of Hematology, Centre Hospitalier Universitaire Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Guillaume Chaby
- Department of Dermatology, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | - Patrice Ceballos
- Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Yannick Le Corre
- Department of Dermatology, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Sébastien Maury
- Department of Hematology, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Jacques-Olivier Bay
- Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Henri Adamski
- Department of Dermatology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Emmanuel Bachy
- Department of Hematology, Centre Hospitalier Universitaire de Lyon, Lyon, France
| | - Edouard Forcade
- Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | - Gérard Socié
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Sylvie Chevret
- Department of Biostatistics, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France; Institut National de la Santé et de la Recherche Médicale U1153, Paris, France
| | - Régis Peffault de Latour
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France.
| |
Collapse
|
13
|
Masson AD, Ram-Wolff C, Bouaziz JD, Cayuela JM, Lorillon G, Frumholtz L, Cassius C, Petit A, Léonard-Louis S, Battistella M, Vignon-Pennamen MD, Rivet J, Meignin V, Duverger L, Jachiet M, Bagot M, Lazaridou I. Dermatomyositis versus mycosis fungoides: Challenges in the diagnosis of erythroderma with associated myositis. Ann Dermatol Venereol 2023; 150:129-133. [PMID: 36682974 DOI: 10.1016/j.annder.2021.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Revised: 03/21/2021] [Accepted: 04/12/2021] [Indexed: 01/22/2023]
Affiliation(s)
- A de Masson
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France; Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France
| | - C Ram-Wolff
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - J D Bouaziz
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France; Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France
| | - J M Cayuela
- Laboratory of Hematology, University Hospital Saint-Louis AP-HP and EA3518 Université de Paris, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - G Lorillon
- Department of Pulmonology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - L Frumholtz
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - C Cassius
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France; Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France
| | - A Petit
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - S Léonard-Louis
- Department of Neuropathology, AP-HP, Pitié Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - M Battistella
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - M D Vignon-Pennamen
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - J Rivet
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - V Meignin
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - L Duverger
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - M Jachiet
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - M Bagot
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France; Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France.
| | - I Lazaridou
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| |
Collapse
|
14
|
Laurent C, Ram-Wolff C, Ingen-Housz-Oro S, Beylot-Barry M, Barete S, Saillard C, Dupuy A, Bagot M, Adamski H. Bone involvement in primary cutaneous diffuse large B-cell lymphoma, leg-type. Clin Exp Dermatol 2023; 48:116-120. [PMID: 36730524 DOI: 10.1093/ced/llac044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 10/05/2022] [Indexed: 01/12/2023]
Abstract
Primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) is an aggressive cutaneous lymphoma. Bone involvement is rare and poorly described. We present five cases of PCDLBCL-LT with bone localization. In four cases, the bone involvement was diagnosed during the initial staging with positron emission tomography (PET) or computed tomography (CT) scan, and in the fifth case after tibial fracture during treatment with rituximab (RTX) and polychemotherapy (PCT). PCDLBCL-LT can be asymptomatic and involve bone sites distant from cutaneous lesions. None had other extracutaneous involvement. In our series, all patients received RTX-PCT as first-line chemotherapy and all had early relapses or progression. Second-line treatments had poor efficacy. Our series shows that bone involvement seems to be associated with poor prognosis in PCDLBCL-LT. Bone localization is not diagnosed with initial thoracic-abdominal-pelvic CT when asymptomatic and affecting the limbs only. If there is a suspicion of PCDLBCL-LT, patients should undergo systematic investigation with alternative imaging techniques, including PET, both at baseline and if there is any concern during follow-up.
Collapse
Affiliation(s)
- Claire Laurent
- Department of Dermatology, University Hospital of Rennes, Rennes, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Paris, France.,French Study Group on Cutaneous Lymphomas (GFELC)
| | - Saskia Ingen-Housz-Oro
- French Study Group on Cutaneous Lymphomas (GFELC).,Department of Dermatology, AP-HP, Henri-Mondor Hospital, Créteil, France
| | - Marie Beylot-Barry
- French Study Group on Cutaneous Lymphomas (GFELC).,Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Stephane Barete
- French Study Group on Cutaneous Lymphomas (GFELC).,Department of Dermatology, Pitié-Salpetrière Hospital, Paris, France
| | - Clemence Saillard
- Department of Dermatology, University Hospital of Rennes, Rennes, France
| | - Alain Dupuy
- Department of Dermatology, University Hospital of Rennes, Rennes, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, Paris, France.,French Study Group on Cutaneous Lymphomas (GFELC)
| | - Henri Adamski
- Department of Dermatology, University Hospital of Rennes, Rennes, France.,French Study Group on Cutaneous Lymphomas (GFELC)
| |
Collapse
|
15
|
De Clippele D, Frumholtz L, Vignon-Pennamen MD, Molina T, Moatti H, Battistella M, Ochmann M, Ram-Wolff C, Petit A, Bagot M, De Masson A. Periorbital erythema and oedema revealing angioimmunoblastic T cell lymphoma. Eur J Dermatol 2023; 33:58-59. [PMID: 37178041 DOI: 10.1684/ejd.2023.4426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Affiliation(s)
| | - Laure Frumholtz
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | | | - Thierry Molina
- Université Paris Cité, Paris, France, Department of Pathology, APHP, Necker, Paris, France
| | - Hannah Moatti
- Department of Hematology, APHP, Saint-Louis Hospital, Paris, France
| | - Maxime Battistella
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France, Université Paris Cité, Paris, France
| | - Marlène Ochmann
- Department of Hematology, Centre Hospitalier Régional d'Orléans, Orléans, France
| | | | - Antoine Petit
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France, Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
| | - Adèle De Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France, Université Paris Cité, Paris, France
| |
Collapse
|
16
|
Lazaridou I, Calvani J, Annabi E, Moins-Teisserenc H, Ta VA, Rivet J, Ram-Wolff C, Dumont M, Mahevas T, Vignon-Pennamen MD, Mourah S, Bouaziz JD, Louveau B, Bagot M, Battistella M, de Masson A. Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol 2023; 37:e715-e717. [PMID: 36645855 DOI: 10.1111/jdv.18868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 01/09/2023] [Indexed: 01/18/2023]
Affiliation(s)
- Ingrid Lazaridou
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Julien Calvani
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| | - Elissa Annabi
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Hélène Moins-Teisserenc
- Université Paris Cité, Paris, France.,Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France.,INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | - Van Anh Ta
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | - Jacqueline Rivet
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
| | | | - Maëlle Dumont
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Thibault Mahevas
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | | | - Samia Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France.,Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Jean-David Bouaziz
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| | - Baptiste Louveau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France.,Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| | - Maxime Battistella
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| | - Adèle de Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| |
Collapse
|
17
|
Welfringer-Morin A, Barroil M, Fraitag S, Szablewski V, Boccara O, Lacour JP, Chiaverini C, Bagot M, Ram-Wolff C, Vignon-Pennamen MD, Dalle S, D'incan M, Amatore F, Beylot-Barry M, Vergier B, Mazereeuw-Hautier J, Tedbirt B, Quereux G, Carpentier O, Skowron F, Bertrand Y, Van Eeckhout P, Dekeuleneer V, Nardin C, Adamski H, Ingen-Housz-Oro S, Dereure O, Bodemer C. Clinical Features, Histological Characteristics, and Disease Outcomes of Mycosis Fungoides in Children and Adolescents: A Nationwide Multicentre Cohort of 46 Patients. Dermatology 2022; 239:132-139. [PMID: 36349768 DOI: 10.1159/000526788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 06/21/2022] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Our objective was to describe the clinical, histological characteristics, and disease outcome of a cohort of mycosis fungoides (MF) diagnosed during childhood including disease status at adulthood. METHODS This is a retrospective multicentre survey of patients aged under 18 years at diagnosis with histologically confirmed MF. Patients' clinical and histological characteristics, treatments, and disease outcome (for patients followed for more than 12 months) were analysed. RESULTS Forty-six patients were included (median age at diagnosis: 11 years; M:F sex ratio: 3:1) with 39 (85%) followed for at least 12 months. Thirty-nine patients (85%) had stage I MF. Hypopigmented patches were observed in 48% and folliculotropism in 43% patients. Immunophenotype of the skin infiltrate was predominantly CD8+ in 17% of patients. Initial management included a wait-and-see strategy in 6/39 (15%), skin-directed treatment in 27 (69%), and systemic treatment in 6 (15%) patients, respectively, with partial or complete clinical response (PR or CR) observed in 28 patients (72%). 14/39 patients (36%) relapsed after initial response. After a median follow-up period of 54 months, disease status at last news was PR or CR in 31/39 (79%), stable disease in 6 (15%), and progression in 2 (5%) patients. Histological transformation was observed in 3/39 (8%). Of the 15 patients followed until adulthood, 13 (87%) had persistent MF. DISCUSSION This survey confirms the high frequency of hypopigmented and folliculotropic lesions and of CD8+ immunophenotype compared to adult MF patients. The long-term course is usually indolent but transformation may occur sometimes long after disease onset and the disease may persist during adulthood.
Collapse
Affiliation(s)
- Anne Welfringer-Morin
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France,
| | - Marion Barroil
- Department of Dermatology, University of Montpellier and INSERM U1058, Montpellier, France
| | - Sylvie Fraitag
- Department of Pathology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| | | | - Olivia Boccara
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| | - Jean-Philippe Lacour
- Department of Dermatology, CHU de Nice, Université Nice Côte d'Azur, Nice, France
| | - Christine Chiaverini
- Department of Dermatology, CHU de Nice, Université Nice Côte d'Azur, Nice, France
| | - Martine Bagot
- Department of Dermatology, Hospital Saint Louis, APHP. Université de Paris, INSERM UMR 976, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Hospital Saint Louis, APHP. Université de Paris, INSERM UMR 976, Paris, France
| | | | - Stéphane Dalle
- Department of Dermatology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
| | - Michel D'incan
- Department of Dermatology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Florent Amatore
- Department of Dermatology, Hospital la Timone, Université Aix-Marseille, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - Marie Beylot-Barry
- Department of Dermatology, CHU de Bordeaux, INSERM U1053 Oncogenèse des lymphomes cutanés, Université de Bordeaux, Bordeaux, France
| | - Béatrice Vergier
- Department of Pathology, CHU de Bordeaux, INSERM U1053 Oncogenèse des lymphomes cutanés, Université de Bordeaux, Bordeaux, France
| | | | | | - Gaelle Quereux
- Department of Dermatology, Hotel Dieu, CHU de Nantes, Nantes, France
| | - Olivier Carpentier
- Department of Dermatology, Hospital Claude Huriez, CHRU Lille, Lille, France
| | | | - Yves Bertrand
- Department of Hematology, Institut d'hématologie et oncologie pediatrique, Lyon, France
| | - Pascal Van Eeckhout
- Department of Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Valérie Dekeuleneer
- Department of Dermatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Charlee Nardin
- Department of Dermatology, CHU de Besancon, INSERM UMR 1098, Université de Franche-Comté, Besancon, France
| | - Henri Adamski
- Department of Dermatology, CHU Pontchaillou, Rennes, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Hospital Henri Mondor, APHP, University Paris Est Créteil EpiDermE, Creteil, France
| | - Olivier Dereure
- Department of Dermatology, University of Montpellier and INSERM U1058, Montpellier, France
| | - Christine Bodemer
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| |
Collapse
|
18
|
Habault J, Thonnart N, Ram-Wolff C, Bagot M, Bensussan A, Poyet JL, Marie-Cardine A. Validation of AAC-11-Derived Peptide Anti-Tumor Activity in a Single Graft Sézary Patient-Derived Xenograft Mouse Model. Cells 2022; 11:cells11192933. [PMID: 36230895 PMCID: PMC9564267 DOI: 10.3390/cells11192933] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 09/12/2022] [Accepted: 09/15/2022] [Indexed: 11/16/2022] Open
Abstract
Sézary syndrome (SS) is an aggressive cutaneous T cell lymphoma with poor prognosis mainly characterized by the expansion of a tumor CD4+ T cell clone in both skin and blood. So far, the development of new therapeutic strategies has been hindered by a lack of reproducible in vivo models closely reflecting patients’ clinical features. We developed an SS murine model consisting of the intravenous injection of Sézary patients’ PBMC, together with a mixture of interleukins, in NOD-SCID-gamma mice. Thirty-four to fifty days after injection, mice showed skin disorders similar to that observed in patients, with the detection of epidermis thickening and dermal tumor T cell infiltrates. Although experimental variability was observed, Sézary cells could be tracked in the blood stream, confirming that our model could efficiently exhibit both skin and blood involvement. Using this model, we evaluated the therapeutic potential of RT39, a cell-penetrating peptide derived from the survival protein anti-apoptosis clone 11 (AAC-11), that we previously characterized as specifically inducing apoptosis of Sézary patients’ malignant clone ex vivo. Systemic administration of RT39 led to cutaneous tumor T cells depletion, demonstrating efficient malignant cells’ targeting and a favorable safety profile. These preclinical data confirmed that RT39 might be an innovative therapeutic tool for Sézary syndrome.
Collapse
Affiliation(s)
- Justine Habault
- INSERM U976 Team 1, Onco-Dermatology and Therapies, 75010 Paris, France
- Saint Louis Research Institute, Université Paris Cité, 75010 Paris, France
| | - Nicolas Thonnart
- INSERM U976 Team 1, Onco-Dermatology and Therapies, 75010 Paris, France
- Saint Louis Research Institute, Université Paris Cité, 75010 Paris, France
| | - Caroline Ram-Wolff
- INSERM U976 Team 1, Onco-Dermatology and Therapies, 75010 Paris, France
- Saint Louis Research Institute, Université Paris Cité, 75010 Paris, France
- Department of Dermatology, Saint Louis Hospital, AP-HP, 75010 Paris, France
| | - Martine Bagot
- INSERM U976 Team 1, Onco-Dermatology and Therapies, 75010 Paris, France
- Saint Louis Research Institute, Université Paris Cité, 75010 Paris, France
- Department of Dermatology, Saint Louis Hospital, AP-HP, 75010 Paris, France
| | - Armand Bensussan
- INSERM U976 Team 1, Onco-Dermatology and Therapies, 75010 Paris, France
- Saint Louis Research Institute, Université Paris Cité, 75010 Paris, France
| | - Jean-Luc Poyet
- INSERM U976 Team 1, Onco-Dermatology and Therapies, 75010 Paris, France
- Saint Louis Research Institute, Université Paris Cité, 75010 Paris, France
| | - Anne Marie-Cardine
- INSERM U976 Team 1, Onco-Dermatology and Therapies, 75010 Paris, France
- Saint Louis Research Institute, Université Paris Cité, 75010 Paris, France
- Correspondence:
| |
Collapse
|
19
|
Dobos G, Battistella M, Ram-Wolff C, Seerror K, de Masson A, Boccara D, Mimoun M, Bagot M, Bensussan A. Distinction between CTCL and inflammatory dermatoses using mRNA expression of cancer-associated fibroblast markers from skin biopsies. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00605-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Mitsunaga K, Bagot M, Beylot-Barry M, Ram-Wolff C, Guenova E, Fassnacht C, Hodak E, Amitay I, Papadavid E, Jonak C, Porkert S, Scarisbrick J, Applewaite R, Nicolay J, Quaglino P, Sanches Jr J, Martins JC, Ortiz-Romero PL. Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas: an EORTC CLTF study. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00599-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Battesti GB, Thonnart N, Bozonnat A, Ram-Wolff C, de Masson A, Bensussan A, Bagot M, Marie-Cardine A, Battistella M. Characterization of CD39 expression in cutaneous T cell lymphomas. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00606-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Dobos G, Ram-Wolff C, Moins H, de Masson A, Bensussan A, Bagot M, Michel L. Early detection of relapse in Sézary syndrome: the added value of KIR3DL2, T-plastin, Twist and Tox for clinical routine. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00611-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Amatore FA, Barre M, Orlanducci F, Lopez M, Castellano R, Ram-Wolff C, Gorvel L, Goubard A, Gaudy-Marqueste C, Bagot M, Bensussan A, Delaporte E, Olive D. Chimerized anti-ICOS 314.8 monoclonal antibodies inhibit tumor cells and regulatory T cells in patients with Sézary syndrome. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00580-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
24
|
Delaleu J, Lepelletier C, Calugareanu A, De Masson A, Charvet E, Petit A, Giurgea I, Amselem S, Karabina S, Jachiet M, Mahevas T, Ram-Wolff C, Vignon-Pennamen MD, Bagot M, Battistella M, Bouaziz JD. Neutrophilic dermatoses. Rev Med Interne 2022; 43:727-738. [PMID: 35870984 DOI: 10.1016/j.revmed.2022.06.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 04/27/2022] [Accepted: 06/12/2022] [Indexed: 10/17/2022]
Abstract
Neutrophilic dermatoses (ND) are a group of inflammatory skin conditions characterized by a neutrophilic infiltrate on histopathology with no evidence of infection. ND are classified based upon the localization of neutrophils within the skin and clinical features. Recent findings suggest that ND are due to two main mechanisms: i) a polyclonal hereditary activation of the innate immune system (polygenic or monogenic); or ii) a clonal somatic activation of myeloid cells such as encountered in myelodysplastic syndrome or VEXAS syndrome. ND belong to internal medicine as a great number of patients with ND suffer from an underlying condition (such as hematological malignancy, inflammatory bowel disease, auto-immune and auto-inflammatory diseases). ND are diagnoses of exclusion and physicians should always consider differential diagnoses, particularly skin infections. Here, we review the pathophysiology and classification of the main ND (i.e., subcorneal pustular dermatosis (Sneddon-Wilkinson Disease) and Intercellular IgA dermatoses, aseptic pustulosis of the folds, Sweet syndrome, neutrophilic eccrine hidradenitis, pyoderma gangrenosum, erythema elevatum diutinum, neutrophilic urticarial dermatosis and neutrophilic panniculitis), their clinical and histopathological features, and we highlight the investigations that are useful to identify ND-associated diseases and to exclude the differential diagnoses.
Collapse
Affiliation(s)
- J Delaleu
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France; Inserm u933, "Childhood genetic disorders", service de génétique, Sorbonne université, hôpital Armand-Trousseau, AP-HP, Paris, France
| | - C Lepelletier
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France
| | - A Calugareanu
- Service de dermatologie, Severe Cutaneous Adverse Reaction (SCAR) Regional Center, HCL, CHU de Lyon Centre, Lyon, France
| | - A De Masson
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France
| | - E Charvet
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France
| | - A Petit
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France
| | - I Giurgea
- Inserm u933, "Childhood genetic disorders", service de génétique, Sorbonne université, hôpital Armand-Trousseau, AP-HP, Paris, France
| | - S Amselem
- Inserm u933, "Childhood genetic disorders", service de génétique, Sorbonne université, hôpital Armand-Trousseau, AP-HP, Paris, France
| | - S Karabina
- Inserm u933, "Childhood genetic disorders", service de génétique, Sorbonne université, hôpital Armand-Trousseau, AP-HP, Paris, France
| | - M Jachiet
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France
| | - T Mahevas
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France
| | - C Ram-Wolff
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France
| | - M-D Vignon-Pennamen
- Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France; Service d'anatomie pathologique, hôpital Saint-Louis, AP-HP, Paris, France
| | - M Bagot
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France
| | - M Battistella
- Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France; Service d'anatomie pathologique, hôpital Saint-Louis, AP-HP, Paris, France
| | - J-D Bouaziz
- Service de dermatologie, hôpital Saint-Louis, AP-HP, Paris, France; Inserm u976 "Human Immunology, Pathophysiology and Immunotherapy", université Paris Cité, Paris, France.
| |
Collapse
|
25
|
Giustiniani J, Dobos G, Moins-Teisserenc H, Eustaquio T, Battistella M, Ortonne N, Ram-Wolff C, Bouaziz JD, Marie-Cardine A, Mourah S, Bagot M, Kupper TS, Clark RA, Bensussan A, de Masson A. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas. Blood Adv 2022; 6:3507-3512. [PMID: 35201316 PMCID: PMC9198911 DOI: 10.1182/bloodadvances.2021006512] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 02/13/2022] [Indexed: 11/20/2022] Open
Affiliation(s)
- Jérôme Giustiniani
- INSERM, U955, Henri Mondor Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Gabor Dobos
- Department of Dermatology, AP-HP, Saint Louis Hospital, Paris, France
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France
- Department of Dermatology, Charité Hospital, Berlin, Germany
| | - Hélène Moins-Teisserenc
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, Unité Mixte de Recherche 1160, Paris, France
- Department of Hematology, AP-HP, Saint Louis Hospital, Paris, France
| | | | - Maxime Battistella
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France
- Department of Pathology, AP-HP, Saint Louis Hospital, Paris, France
| | - Nicolas Ortonne
- INSERM, U955, Henri Mondor Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
- Department of Pathology, Henri Mondor Hospital, AP-HP, Paris, France
| | | | - Jean-David Bouaziz
- Department of Dermatology, AP-HP, Saint Louis Hospital, Paris, France
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France
| | - Anne Marie-Cardine
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France
| | - Samia Mourah
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France
- Department of Tumor Genomics and Pharmacology, AP-HP, Saint Louis Hospital, Paris, France; and
| | - Martine Bagot
- Department of Dermatology, AP-HP, Saint Louis Hospital, Paris, France
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France
| | - Thomas S. Kupper
- Department of Dermatology, Dana Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA
| | - Rachael A. Clark
- Department of Dermatology, Dana Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA
| | - Armand Bensussan
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France
| | - Adèle de Masson
- Department of Dermatology, AP-HP, Saint Louis Hospital, Paris, France
- Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- INSERM, UMR 976 “Human Immunology, Pathophysiology and Immunotherapy,” Paris, France
| |
Collapse
|
26
|
Galadari A, Ram-Wolff C, Al Hage J, Battistella M, Vignon-Pennamen MD, Rivet J, Cayuela JM, Gabison G, Moins-Teisserenc H, Mourah S, Ingen-Housz-Oro S, Le Corre Y, Bagot M, de Masson A. Cutaneous Gamma Delta T-Cell Lymphoma with indolent evolution: A series of five cases. J Eur Acad Dermatol Venereol 2022; 36:e715-e717. [PMID: 35535450 DOI: 10.1111/jdv.18204] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Accepted: 05/03/2022] [Indexed: 12/01/2022]
Affiliation(s)
- A Galadari
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France
| | - C Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - J Al Hage
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France
| | - M Battistella
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,Department of Pathology, Saint-Louis Hospital, APHP, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - M D Vignon-Pennamen
- Department of Pathology, Saint-Louis Hospital, APHP, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - J Rivet
- Department of Pathology, Saint-Louis Hospital, APHP, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - J M Cayuela
- Université de Paris, Paris, France.,Laboratory of Hematology and EA3518, Saint-Louis Hospital, APHP, Paris, France
| | - G Gabison
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France
| | - H Moins-Teisserenc
- Université de Paris, Paris, France.,Laboratory of Hematology and INSERM U1160, Saint-Louis Hospital, APHP, Paris, France
| | - S Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,Department of Pharmacology and Tumor Genomics, Saint-Louis Hospital, Paris, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor Hospital, APHP, Créteil, France.,Univ Paris Est Créteil Epiderme, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - Y Le Corre
- Department of Dermatology, Centre University Hospital of Angers, Angers, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - M Bagot
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - A de Masson
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| |
Collapse
|
27
|
André R, Ram-Wolff C, Bagot M. Clinical characteristics of Mycosis fungoides palmaris et plantaris: two cases and a systematic literature review. Eur J Dermatol 2022; 32:421-423. [PMID: 36065530 PMCID: PMC9660025 DOI: 10.1684/ejd.2021.4126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Raphaël André
- grid.8591.50000 0001 2322 4988Department of Dermatology, Geneva Hospitals, Geneva University, Geneva, Switzerland
| | - Caroline Ram-Wolff
- grid.462420.60000 0004 0638 4500Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - Martine Bagot
- grid.462420.60000 0004 0638 4500Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| |
Collapse
|
28
|
Wang J, Ram-Wolff C, Dobos G, Al Hage J, Grange F, Rivet J, Vignon-Pennamen MD, Moins-Teisserenc H, Boisson M, Moegle C, Sadoux A, Mourah S, Battistella M, Bagot M, de Masson A. Head and Neck granulomatous Rash Associated with Mogamulizumab Mimicking Mycosis Fungoides. Br J Dermatol 2022; 187:129-131. [PMID: 35083741 DOI: 10.1111/bjd.21030] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Revised: 01/04/2022] [Accepted: 01/17/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Jingying Wang
- Department of Dermatology, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Gabor Dobos
- Department of Dermatology, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Jana Al Hage
- Department of Dermatology, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Florent Grange
- Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | - Jacqueline Rivet
- Department of Pathology, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | | | - Hélène Moins-Teisserenc
- Biological Hematology Laboratory, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Marie Boisson
- Pharmacogenomics Laboratory, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Céline Moegle
- Department of Dermatology, Mulhouse Sud Alsace Hospital, Mulhouse, France
| | - Aurélie Sadoux
- Pharmacogenomics Laboratory, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Samia Mourah
- Pharmacogenomics Laboratory, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Maxime Battistella
- Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| | - Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
| |
Collapse
|
29
|
Roelens M, de Masson A, Andrillon A, Ram-Wolff C, Biard L, Boisson M, Mourah S, Battistella M, Toubert A, Bagot M, Moins-Teisserenc H. Mogamulizumab induces long term immune restoration and reshapes tumor heterogeneity in Sézary syndrome. Br J Dermatol 2022; 186:1010-1025. [PMID: 35041763 DOI: 10.1111/bjd.21018] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 12/20/2021] [Accepted: 01/15/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND Mogamulizumab, an anti-CCR4 monoclonal antibody, has been shown to increase progression-free survival in cutaneous T-cell lymphoma. OBJECTIVES We hypothesized that besides the targeted depletion of Sézary cells (SCs), mogamulizumab may reshape the immune tumor microenvironment. METHODS Both malignant and benign compartments from 26 Sézary patients with B2 stage before mogamulizumab initiation were prospectively analyzed using KIR3DL2 and TCR-Vβ markers, serological markers and molecular assessments of clonality. RESULTS Prior to mogamulizumab, the benign subset of CD4+ T-cells displayed exhausted phenotypes, with an increased gradient in PD1/TIGIT/DNAM/CD27/CD28 and CD70 expression from age- matched controls to patient benign CD4+T cells and to SCs. All patients presented SCs with heterogeneous phenotypes and differential expression of individual markers were found within distinct malignant subsets. Early complete blood response was observed in 17/26 patients and was associated to a higher baseline CCR4 expression. A drastic decrease in benign T cells and activated Treg counts was observed during the first 4 weeks. Long-term follow-up revealed the emergence of an immune restoration involving CD8+, naive and stem-memory CD4+T cells, with almost complete disappearance of exhausted lymphocytes. Development of resistance/tumor escape to mogamulizumab was associated to the emergence of CCR4- SCs in blood and skin, displaying significant changes in their heterogeneity patterns, and not univocally explained by mutations within CCR4 coding regions. CONCLUSIONS Mogamulizumab is likely contributing to the restoration of an efficient immunity and reshapes not only the malignant lymphocyte subset but also the benign subset. These results have potential implications for optimal therapeutic sequences and/or combinations.
Collapse
Affiliation(s)
- Marie Roelens
- INSERM UMR 1160, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France
| | - Adèle de Masson
- Université de Paris, Paris, France.,INSERM UMR 976, Institut de Recherche Saint-Louis, Paris, France.,Dermatology Department, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Anais Andrillon
- Université de Paris, Paris, France.,INSERM, UMR 1153, Hôpital Saint-Louis, AP-HP, Paris, France
| | | | - Lucie Biard
- Université de Paris, Paris, France.,INSERM, UMR 1153, Hôpital Saint-Louis, AP-HP, Paris, France.,Department of Biostatistics and Medical Information, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Marie Boisson
- Tumor Genomics and Pharmacology Department, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Samia Mourah
- Université de Paris, Paris, France.,INSERM UMR 976, Institut de Recherche Saint-Louis, Paris, France.,Tumor Genomics and Pharmacology Department, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Maxime Battistella
- Université de Paris, Paris, France.,INSERM UMR 976, Institut de Recherche Saint-Louis, Paris, France.,Pathology Department, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Antoine Toubert
- INSERM UMR 1160, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,Immunology Laboratory, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Martine Bagot
- Université de Paris, Paris, France.,INSERM UMR 976, Institut de Recherche Saint-Louis, Paris, France.,Dermatology Department, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Helene Moins-Teisserenc
- INSERM UMR 1160, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,Hematology Laboratory, Hôpital Saint-Louis, AP-HP, Paris, France
| |
Collapse
|
30
|
Dobos G, Miladi M, Michel L, Ram-Wolff C, Battistella M, Bagot M, de Masson A. Recent advances on cutaneous lymphoma epidemiology. Presse Med 2022; 51:104108. [PMID: 35026392 DOI: 10.1016/j.lpm.2022.104108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 11/26/2021] [Accepted: 01/05/2022] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Primary cutaneous lymphomas are a group of T- (CTCL) and B-cell (CBCL) malignancies. These diseases have different clinical presentations and prognosis. Our knowledge on their epidemiology is limited. Aim of this review was to summarise recent findings on the incidence of CTCL and CBCL, how they change over time, and to describe possible causes and consequences. We found that although there are important differences in the epidemiology of cutaneous lymphomas in different countries, the relative frequency of certain, especially rare lymphomas remains stable. Several studies described growing incidences of both CTCL and CBCL. The emergence of new diagnostic criteria, a more precise definition of the entities and new biomarkers enable a better classification of cases.
Collapse
Affiliation(s)
- G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France; INSERM U976 Human Immunology, Pathophysiology and Immune Therapies, Paris, France; Université de Paris, Paris, France; Department of Dermatology, Venerology and Allergology, Charité-Universitätsmedizin Berlin, Germany
| | - M Miladi
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - L Michel
- INSERM U976 Human Immunology, Pathophysiology and Immune Therapies, Paris, France; Université de Paris, Paris, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M Battistella
- INSERM U976 Human Immunology, Pathophysiology and Immune Therapies, Paris, France; Université de Paris, Paris, France; Pathology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France; INSERM U976 Human Immunology, Pathophysiology and Immune Therapies, Paris, France; Université de Paris, Paris, France.
| | - A de Masson
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France; INSERM U976 Human Immunology, Pathophysiology and Immune Therapies, Paris, France; Université de Paris, Paris, France
| |
Collapse
|
31
|
Dobos G, Calugareanu A, Michel L, Battistella M, Ram-Wolff C, Bouaziz JD, Bensussan A, de Masson A, Bagot M. Exploring the role of the skin microenvironment in cutaneous T-cell lymphoma using single cell RNA-sequencing. Eur J Cancer 2021; 156 Suppl 1:S3-S4. [PMID: 34649652 DOI: 10.1016/s0959-8049(21)00631-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Gabor Dobos
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; Department of Dermatology, Venerology and Allergology, Charité-Universitaetsmedizin Berlin, Berlin, Germany; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Andreea Calugareanu
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Laurence Michel
- UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Maxime Battistella
- UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France; Department of Pathology, Saint-Louis Hospital, APHP, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Jean-David Bouaziz
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Armand Bensussan
- UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| |
Collapse
|
32
|
Dobos G, Miladi M, Roelens M, Ram-Wolff C, de Masson A, Michel L, Battistella M, Mourah S, Bensussan A, Moins-Teisserenc H, Bagot M. Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker. Eur J Cancer 2021; 156 Suppl 1:S6-S7. [PMID: 34649664 DOI: 10.1016/s0959-8049(21)00638-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Gabor Dobos
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France; Department of Dermatology, Venerology and Allergology, Charité-Universtaetsmedizin Berlin, Berlin, Germany
| | - Maryam Miladi
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France
| | - Marie Roelens
- Laboratoire d'Hematologie Biologique, UMR-1160, INSERM, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Laurence Michel
- UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | - Maxime Battistella
- UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France; Department of Pathology, Saint-Louis Hospital, APHP, Paris, France
| | - Samia Mourah
- Department of Tumor Genomics and Pharmacology, Saint Louis Hospital, APHP, Paris, France
| | - Armand Bensussan
- UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| | | | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France; UMR-976, HIPI (Immunologie humaine, Pathophysiologie, Immunothérapie), INSERM, Paris, France
| |
Collapse
|
33
|
Battesti G, Mahevas T, Lepelletier C, Teboul A, Renaud L, Moulonguet I, Vignon-Pennamen MD, Battistella M, Ram-Wolff C, Bagot M, de Masson A. Intravascular relapse of an extra-nodal NK/T-cell lymphoma, nasal-type, presenting as diffuse and eruptive telangiectasia. Eur J Cancer 2021; 156 Suppl 1:S63-S64. [PMID: 34649666 DOI: 10.1016/s0959-8049(21)00745-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Gilles Battesti
- Department of dermatology, Saint-Louis Hospital, Paris, France
| | | | | | | | - Loic Renaud
- Department of hematology, Saint-Louis Hospital, Paris, France
| | | | | | | | | | - Martine Bagot
- Department of dermatology, Saint-Louis Hospital, Paris, France
| | - Adèle de Masson
- Department of dermatology, Saint-Louis Hospital, Paris, France
| |
Collapse
|
34
|
Battesti G, Ram-Wolff C, Dobos G, Aubin F, Algros MP, Guenova E, Joly P, Courville P, Mourah S, Cayuela JM, Moins-Tesserenc H, Battistella M, Vignon-Pennamen MD, Rivet J, Bagot M, de Masson A. Granulomatous slack skin: clinical retrospective study of 8 cases of the Cutaneous Lymphoma French Study Group. Eur J Cancer 2021; 156 Suppl 1:S35-S36. [PMID: 34649654 DOI: 10.1016/s0959-8049(21)00690-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Gilles Battesti
- Department of Dermatology, Saint-Louis Hospital, Paris, France
| | | | - Gabor Dobos
- Department of Dermatology, Saint-Louis Hospital, Paris, France
| | - François Aubin
- Department of Dermatology, University Hospital, Besançon, France
| | | | - Emmanuella Guenova
- Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland; University of Lausanne, Lausanne, Switzerland; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | - Pascal Joly
- Department of Dermatology, Rouen University Hospital, Rouen, France
| | | | - Samia Mourah
- Department of Pharmacology and Tumor Genomics, Saint-Louis Hospital, Paris, France; University of Paris, Paris, France
| | | | | | | | | | | | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, Paris, France
| | - Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, Paris, France
| |
Collapse
|
35
|
Galadari A, Ram-Wolff C, Al Hage J, De Masson A, Battistella M, Oro S, Le Corre Y, Bagot M. Indolent primary cutaneous T-cell gamma delta lymphomas: a first illustrated series of 5 cases. Eur J Cancer 2021; 156 Suppl 1:S70-S71. [PMID: 34649670 DOI: 10.1016/s0959-8049(21)00758-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Alia Galadari
- Department of Dermatology, Saint-Louis Hospital, Paris, France
| | | | - Jana Al Hage
- Department of Dermatology, Saint-Louis Hospital, Paris, France
| | - Adele De Masson
- Department of Dermatology, Saint-Louis Hospital, Paris, France
| | | | - Saskia Oro
- Department of Dermatology, Henri Mondor Hospital, Paris, France
| | | | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, Paris, France
| |
Collapse
|
36
|
Wang J, de Masson A, Ram-Wolff C, Dobos G, Al Hage J, Rivet J, Vignon-Pennamen MD, Moins-Teisserenc H, Boisson M, Sadoux A, Mourah S, Battistella M, Bagot M. Granulomatous rash associated with mogamulizumab mimicking mycosis fungoides: a case series. Eur J Cancer 2021; 156 Suppl 1:S49. [PMID: 34649659 DOI: 10.1016/s0959-8049(21)00716-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jingying Wang
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France; Department of Dermatology, Ruijin Hospital, Université Jiaotong de Shanghai, Shanghai, China
| | - Adèle de Masson
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | | | - Gabor Dobos
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France; Department of Dermatology, Venerology and Allergology, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Jana Al Hage
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | | | | | | | - Marie Boisson
- Tumor Genomics and Pharmacology Department, APHP, Saint-Louis Hospital, Paris, France
| | - Aurelie Sadoux
- Tumor Genomics and Pharmacology Department, APHP, Saint-Louis Hospital, Paris, France
| | - Samia Mourah
- Tumor Genomics and Pharmacology Department, APHP, Saint-Louis Hospital, Paris, France
| | | | - Martine Bagot
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| |
Collapse
|
37
|
Amatore F, Dereure O, Delaporte E, Ram-Wolff C, Bagot M. Is mogamulizumab-induced alopecia areata associated with favorable outcomes in Sézary syndrome? Eur J Cancer 2021; 156 Suppl 1:S50-S51. [PMID: 34649661 DOI: 10.1016/s0959-8049(21)00719-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Florent Amatore
- Department of Dermatology, Aix Marseille University, APHM, North Hospital, Marseille, France
| | - Olivier Dereure
- Department of Dermatology, Montpellier University, Saint-Eloi Hospital, Montpellier, France
| | - Emmanuel Delaporte
- Department of Dermatology, Aix Marseille University, APHM, North Hospital, Marseille, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Paris University, Saint-Louis Hospital, AP-HP, Paris, France
| | - Martine Bagot
- Department of Dermatology, Paris University, Saint-Louis Hospital, AP-HP, Paris, France
| |
Collapse
|
38
|
Roelens M, de Masson A, Andrillon A, Ram-Wolff C, Biard L, Boisson M, Mourah S, Bagot M, Moins-Teisserenc H. Mogamulizumab induces long term immune restoration and reshapes tumoral heterogeneity in Sézary syndrome. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00661-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
39
|
de Masson A, Darbord D, Dobos G, Boisson M, Roelens M, Ram-Wolff C, Cassius C, Le Buanec H, de la Grange P, Jouenne F, Louveau B, Sadoux A, Bouaziz JD, Marie-Cardine A, Bagot M, Moins-Teisserenc H, Mourah S, Battistella M. Macrophage-derived CXCL9 and CXCL11 recruit CD8 T cells in skin and provide long-term disease control in mogamulizumab-treated CTCL patients. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00662-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
40
|
Campbell BA, Dobos G, Haider Z, Bagot M, Prince HM, McCormack C, Ram-Wolff C, Miladi M, Scarisbrick J. Treatment efficacy for Sézary syndrome: an international, multi-centre, comparative study of current systemic therapies. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00663-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
41
|
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D’Incan M, Grange F, Braniste V, Bagot M. French real-life retrospective study in patients with mycosis fungoides and Sezary syndrome treated by mogamulizumab. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00738-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Calvani J, De Masson A, De Margerie-Mellon C, De Kerviler E, Ram-Wolff C, Gruber A, Meignin V, Brice P, Sadoux A, Mourah S, Bagot M, Battistella M. Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndrome. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00674-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
de Masson A, Zimmermann C, Boisson M, Ram-Wolff C, Sadoux A, Louveau B, Vignon D, Rivet J, Cayuela JM, Dobos G, Moins-Teisserenc H, Roelens M, Gruber A, Lebbé C, Bagot M, Battistella M, Mourah S. Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00626-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
44
|
Zimmermann C, Boisson M, Ram-Wolff C, Sadoux A, Louveau B, Vignon-Pennamen MD, Rivet J, Cayuela JM, Dobos G, Moins-Teisserenc H, Roelens M, Gruber A, Lebbé C, Bagot M, Battistella M, Mourah S, de Masson A. Diagnostic performance of high-throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma. Br J Dermatol 2021; 185:679-680. [PMID: 33942285 DOI: 10.1111/bjd.20432] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 04/30/2021] [Accepted: 04/30/2021] [Indexed: 01/04/2023]
Affiliation(s)
- C Zimmermann
- Dermatology Department, APHP, Saint Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint Louis, Paris, France.,Université de Paris, Paris, France
| | - M Boisson
- Tumor Genomics and Pharmacology Department, APHP, Saint Louis Hospital, Paris, France
| | - C Ram-Wolff
- Dermatology Department, APHP, Saint Louis Hospital, Paris, France
| | - A Sadoux
- Tumor Genomics and Pharmacology Department, APHP, Saint Louis Hospital, Paris, France
| | - B Louveau
- Tumor Genomics and Pharmacology Department, APHP, Saint Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint Louis, Paris, France.,Université de Paris, Paris, France
| | | | - J Rivet
- Pathology Department, APHP, Saint Louis Hospital, Paris, France
| | - J-M Cayuela
- Université de Paris, Paris, France.,Hematology Laboratory, Saint Louis Hospital, Paris, France.,EA3518, Saint Louis Hospital, Paris, France
| | - G Dobos
- Dermatology Department, APHP, Saint Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint Louis, Paris, France.,Université de Paris, Paris, France
| | - H Moins-Teisserenc
- Université de Paris, Paris, France.,Hematology Laboratory, Saint Louis Hospital, Paris, France.,INSERM U1160, Institut de Recherche Saint Louis, Paris, France
| | - M Roelens
- Université de Paris, Paris, France.,INSERM U1160, Institut de Recherche Saint Louis, Paris, France
| | - A Gruber
- Tumor Genomics and Pharmacology Department, APHP, Saint Louis Hospital, Paris, France
| | - C Lebbé
- Dermatology Department, APHP, Saint Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint Louis, Paris, France.,Université de Paris, Paris, France
| | - M Bagot
- Dermatology Department, APHP, Saint Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint Louis, Paris, France.,Université de Paris, Paris, France
| | - M Battistella
- Pathology Department, APHP, Saint Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint Louis, Paris, France.,Université de Paris, Paris, France
| | - S Mourah
- Tumor Genomics and Pharmacology Department, APHP, Saint Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint Louis, Paris, France.,Université de Paris, Paris, France
| | - A de Masson
- Dermatology Department, APHP, Saint Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint Louis, Paris, France.,Université de Paris, Paris, France
| |
Collapse
|
45
|
Skayem C, Beylot-Barry M, de Masson A, Dereure O, Ram-Wolff C, Bagot M, Vergier B, Battistella M, Ortonne N, Ingen-Housz-Oro S. Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases. Br J Dermatol 2021; 185:1061-1063. [PMID: 34128541 DOI: 10.1111/bjd.20580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 06/08/2021] [Accepted: 06/13/2021] [Indexed: 12/01/2022]
Affiliation(s)
- C Skayem
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - M Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.,INSERM U1053, Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France
| | - A de Masson
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - O Dereure
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, University of Montpellier and INSERM U1058 Pathogenesis and Control of Chronic Infections, Montpellier, France
| | - C Ram-Wolff
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - M Bagot
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - B Vergier
- INSERM U1053, Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, Bordeaux University Hospital, Bordeaux, France
| | - M Battistella
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - N Ortonne
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, AP-HP, Henri Mondor Hospital, Créteil, France.,Paris Est Créteil University (UPEC) and IMRB, INSERM U955 Team Ortonne (NFL), Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,University Paris Est Créteil EpiDermE, Créteil, France
| |
Collapse
|
46
|
Bergqvist C, Beylot-Barry M, Ram-Wolff C, Vergier B, Bagot M, Battistella M, Dalle S, Balme B, Merlio JP, Durupt F, Le Corre Y, Bonnet N, Le Bozec P, Skowron F, Vivard-Wallee I, Dereure O, Brunet-Possenti F, Ingen-Housz-Oro S, Ortonne N. Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. Clin Exp Dermatol 2021; 46:1441-1451. [PMID: 33987864 DOI: 10.1111/ced.14730] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Lymphomatoid papulosis (LyP) type D (LyP D) and type E (LyP E) have recently been described in small series of cases or isolated case reports. AIM To further describe the clinical and histological features of LyP D and E based on a retrospective multicentre study. METHODS The clinical and histopathological features of 29 patients with an initial diagnosis of LyP D or LyP E were retrospectively assessed using standardized forms. RESULTS After exclusion of 5 cases, 24 patients (14 LyP D, 10 LyP E) were enrolled in the study. The median follow-up was 2.5 years (range 1 month to 13 years). LyP D was characterized by multiple recurrent self-regressing small papules that developed central erosion or necrosis, whereas LyP E presented as papulonodular lesions that rapidly evolved into necrotic eschar-like lesions > 10 mm in size. Epidermal changes were more frequent in LyP D, whereas dermal infiltrates were deeper in LyP E. Anaplastic cytology was rare and the DUSP22 rearrangement was never observed. Two patients (8%) had an associated cutaneous lymphoma. CONCLUSION LyP D and E have distinct clinical findings and may be associated with other cutaneous lymphomas.
Collapse
Affiliation(s)
- C Bergqvist
- Department of, Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - M Beylot-Barry
- Department of, Dermatology, Bordeaux University Hospital, Bordeaux, France.,Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - C Ram-Wolff
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - B Vergier
- Department of, Pathology, Bordeaux University Hospital, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - M Bagot
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - M Battistella
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Pathology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - S Dalle
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, University Hospital of Lyon-Sud, Lyon, France
| | - B Balme
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, University Hospital of Lyon-Sud, Lyon, France.,Department of, Pathology, University Hospital of Lyon-Sud, Lyon, France
| | - J P Merlio
- Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - F Durupt
- Department of Dermatology, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Y Le Corre
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, CHU Angers, Angers, France
| | - N Bonnet
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, Hôpitaux de Marseille, Marseille, France
| | - P Le Bozec
- Department of Dermatology, AP-HP, Hôpital Beaujon, Clichy, France
| | - F Skowron
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | | | - O Dereure
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, CHU de Montpellier, Montpellier, France
| | - F Brunet-Possenti
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, AP-HP, Hôpital Bichat, Paris, France
| | - S Ingen-Housz-Oro
- Department of, Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - N Ortonne
- Department of, Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France.,Paris Est Creteil University (UPEC) and IMRB, INSERM U955 Team Ortonne (NFL), Créteil, France
| |
Collapse
|
47
|
Quaglino P, Prince H, Cowan R, Vermeer M, Papadavid L, Bagot M, Servitjie O, Berti E, Guenova E, Stadler R, Querfeld C, Busschots A, Hodak E, Patsatsi A, Sanches J, Maule M, Yoo J, Kevin M, Fava P, Ribero S, Zocchi L, Rubatto M, Fierro M, Wehkamp U, Marshalko M, Mitteldorf C, Akilov O, Ortiz-Romero P, Estrach T, Vakeva L, Enz P, Wobser M, Bayne M, Jonak C, Rubeta M, Forbes A, Bates A, Battistella M, Amel-Kashipaz R, Vydianath B, Combalia A, Georgiou E, Hauben E, Hong E, Jost M, Knobler R, Amitay-Laish I, Miyashiro D, Cury-Martins J, Martinez X, Muniesa C, Prag-Naveh H, Nikolaou V, Quint K, Ram-Wolff C, Rieger K, Stranzenbach R, Szepesi Á, Alberti-Violetti S, Felicity E, Cerroni L, Kempf W, Whittaker S, Willemze R, Kim Y, Scarisbrick J. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 2021; 184:722-730. [PMID: 32479678 PMCID: PMC7704558 DOI: 10.1111/bjd.19252] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/22/2020] [Indexed: 02/06/2023]
Abstract
BACKGROUND The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). OBJECTIVES To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. METHODS In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. RESULTS The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81·5%), while a smaller percentage (44 cases, 11·1%) received systemic therapy. Expectant observation was used in 7·3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0·001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0·001), higher modified Severity Weighted Assessment Tool (> 10, 15%; ≤ 10, 7%; P = 0·01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0·001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs. T1a/T2a, odds ratio 3·07) and FMF (odds ratio 2·83). The overall response rate (ORR) to first-line SDT was 73%, while the ORR to first-line systemic treatments was lower (57%) (P = 0·027). Health-related QoL improved significantly both in patients with responsive disease and in those with stable disease. CONCLUSIONS Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.
Collapse
Affiliation(s)
- P. Quaglino
- Dermatologic Clinic, University of Turin Medical School, Torino, Italy
| | - H.M. Prince
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
| | - R. Cowan
- Christie Hospital, Manchester UK
| | - M. Vermeer
- Leiden University Medical Centre, The Netherlands
| | | | - M. Bagot
- Hospital St Louis, Paris, France
| | - O. Servitjie
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | | | | | - R. Stadler
- University Medical Centre, Johannes Wesling, Minden, Germany
| | - C. Querfeld
- City of Hope National Medical Center and Beckman Research Institute, Duarte, California, US
| | | | - E. Hodak
- Rabin Medical Center, Tel Aviv University, Israel
| | - A. Patsatsi
- Aristotle University of Thessaloniki, in Papageorgiou General Hospital, Greece
| | - J. Sanches
- University of Sao Paulo Medical School, Brazil, South America
| | - M. Maule
- Cancer Epidemiology Unit, Department Medical Sciences, University of Turin, Italy
| | - J. Yoo
- University Hospitals Birmingham, UK
| | - M. Kevin
- University Hospitals Birmingham, UK
| | - P. Fava
- Dermatologic Clinic, University of Turin Medical School, Torino, Italy
| | - S. Ribero
- Dermatologic Clinic, University of Turin Medical School, Torino, Italy
| | - L. Zocchi
- Dermatologic Clinic, University of Turin Medical School, Torino, Italy
| | - M. Rubatto
- Dermatologic Clinic, University of Turin Medical School, Torino, Italy
| | - M.T. Fierro
- Dermatologic Clinic, University of Turin Medical School, Torino, Italy
| | - U. Wehkamp
- University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | | | - C. Mitteldorf
- HELIOS Klinikum Hildesheim GmbH, University Medical Center Göttingen, Germany
| | - O. Akilov
- University of Pittsburgh School of Medicine, Pennsylvania, USA
| | | | - T. Estrach
- Hospital Clinico, University of Barcelona, Spain
| | - L. Vakeva
- Helsinki University Central Hospital, Finland
| | - P.A. Enz
- Hospital Italiano De Buenos Aires, Argentina, South America
| | - M. Wobser
- University Hospital Wuerzburg, Germany
| | | | - C. Jonak
- Dept of Dermatology, Medical University of Vienna, Austria
| | - M. Rubeta
- Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford UK
| | | | - A. Bates
- University Hospital Southampton, Southampton, UK
| | | | | | | | - A. Combalia
- Hospital Clinico, University of Barcelona, Spain
| | - E. Georgiou
- Aristotle University of Thessaloniki, in Papageorgiou General Hospital, Greece
| | - E. Hauben
- Belgium University Hospitals Leuven, Leuven, Belgium
| | | | - M. Jost
- University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - R. Knobler
- Dept of Dermatology, Medical University of Vienna, Austria
| | | | - D. Miyashiro
- University of Sao Paulo Medical School, Brazil, South America
| | - J. Cury-Martins
- University of Sao Paulo Medical School, Brazil, South America
| | - X. Martinez
- City of Hope National Medical Center and Beckman Research Institute, Duarte, California, US
| | - C. Muniesa
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | | | | | - K. Quint
- Leiden University Medical Centre, The Netherlands
| | | | | | - R. Stranzenbach
- University Medical Centre, Johannes Wesling, Minden, Germany
| | - Á. Szepesi
- Semmelweis University, Budapest, Hungary
| | | | | | - L. Cerroni
- Department of Dermatology, Research Unit Dermatopathology, Medical University of Graz, Graz, Austria
| | - W. Kempf
- Kempf und Pfaltz, Histologische Diagnostik, Zurich, Switzerland
| | - S. Whittaker
- Kings College London, Guys and St Thomas NHS Foundation Trust, London
| | - R. Willemze
- Leiden University Medical Centre, The Netherlands
| | | | | |
Collapse
|
48
|
Calvani J, de Masson A, de Margerie-Mellon C, de Kerviler É, Ram-Wolff C, Gruber A, Meignin V, Brice P, Sadoux A, Mourah S, Bagot M, Battistella M. Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndrome. Br J Dermatol 2021; 185:419-427. [PMID: 33400272 DOI: 10.1111/bjd.19796] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 12/07/2020] [Accepted: 12/30/2020] [Indexed: 12/24/2022]
Abstract
BACKGROUND The prognosis of Sézary syndrome (SS) and mycosis fungoides (MF) depends on lymph node (LN) involvement. The usefulness of LN image-guided core-needle biopsies (CNBs), instead of surgical sampling, has been poorly evaluated. OBJECTIVES To determine the prognostic value of LN CNB in MF/SS. METHODS A retrospective search was conducted to identify all LN biopsy specimens of MF/SS between 2008 and 2019. Biopsies were staged according to the International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer (ISCL/EORTC) criteria. We performed immunolabelling and determined the tumour clone frequency (TCF) by high-throughput sequencing of the T-cell receptor beta locus. RESULTS We included 119 consecutive biopsies from 100 patients, 45 with MF and 55 with SS. N1, N2 and N3 stages were diagnosed in 34 (29%), 26 (22%) and 59 (49%) cases, respectively. The TCF, Ki67 index, and percentage of cells positive for thymocyte selection-associated high mobility group box protein (TOX), programmed cell death protein 1 (PD1), killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) and cluster of differentiation (CD)30 were all positively correlated with the N stage. Median overall survival (OS) for N1/N2 vs. N3 patients was 42 months (range 26-not reached) vs. 14 months (range 5-30), respectively (P < 0·001). In univariate analyses, an age > 75 years, LN short-axis diameter > 15 mm, N3 stage, presence of large-cell transformation, TOX > 60%, PD1 > 25%, Ki67 > 30%, KIR3DL2 > 15%, CD30 > 10% and TCF > 25% were identified as adverse prognostic factors. In multivariate analyses, only an age > 75 years and Ki67 index > 30% were associated with reduced OS. We developed a new prognostic index associating the N stage and the Ki67 index, which better discriminates N3 patients with poor prognosis. CONCLUSIONS CNB allows an objective assessment of the LN involvement in MF/SS, relevant for staging and prognosis.
Collapse
Affiliation(s)
- J Calvani
- Department of, Pathology, Hôpital Saint-Louis APHP, Paris, France
| | - A de Masson
- Department of, Dermatology, Hôpital Saint-Louis APHP, Paris, France.,INSERM UMR-S976, Université de Paris, Paris, France
| | | | - É de Kerviler
- Department of, Radiology, Hôpital Saint-Louis APHP, Paris, France
| | - C Ram-Wolff
- Department of, Dermatology, Hôpital Saint-Louis APHP, Paris, France.,INSERM UMR-S976, Université de Paris, Paris, France
| | - A Gruber
- Department of, Solid Tumor Genomics, Hôpital Saint-Louis APHP, Paris, France.,INSERM UMR-S976, Université de Paris, Paris, France
| | - V Meignin
- Department of, Pathology, Hôpital Saint-Louis APHP, Paris, France
| | - P Brice
- Department of, Hematology, Assistance Publique Hôpitaux de Paris, Hôpital Saint-Louis APHP, Paris, France
| | - A Sadoux
- Department of, Solid Tumor Genomics, Hôpital Saint-Louis APHP, Paris, France
| | - S Mourah
- Department of, Solid Tumor Genomics, Hôpital Saint-Louis APHP, Paris, France.,INSERM UMR-S976, Université de Paris, Paris, France
| | - M Bagot
- Department of, Dermatology, Hôpital Saint-Louis APHP, Paris, France.,INSERM UMR-S976, Université de Paris, Paris, France
| | - M Battistella
- Department of, Pathology, Hôpital Saint-Louis APHP, Paris, France.,INSERM UMR-S976, Université de Paris, Paris, France
| |
Collapse
|
49
|
Delaleu J, Battistella M, Rathana K, Vignon-Pennamen MD, Laurent C, Ram-Wolff C, Fenaux P, Jachiet M, Zuelgaray E, Bagot M, Bouaziz JD, de Masson A. Identification of clonal skin myeloid cells by next-generation sequencing in myelodysplasia cutis. Br J Dermatol 2020; 184:367-369. [PMID: 32964412 DOI: 10.1111/bjd.19547] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2020] [Revised: 09/04/2020] [Accepted: 09/06/2020] [Indexed: 12/28/2022]
Affiliation(s)
- J Delaleu
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France
| | - M Battistella
- INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,Pathology Department, APHP, Saint-Louis Hospital, Paris, France
| | - K Rathana
- Université de Paris, Paris, France.,Laboratory of Hematology, APHP, Saint-Louis Hospital, Paris, France
| | - M-D Vignon-Pennamen
- INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,Pathology Department, APHP, Saint-Louis Hospital, Paris, France
| | - C Laurent
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | - C Ram-Wolff
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | - P Fenaux
- Université de Paris, Paris, France.,Clinical Hematology Department, APHP, Saint-Louis Hospital, Paris, France
| | - M Jachiet
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | - E Zuelgaray
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | - M Bagot
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France
| | - J-D Bouaziz
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France
| | - A de Masson
- Dermatology Department, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976 'Human Immunology, Pathophysiology and Immunotherapy', Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France
| |
Collapse
|
50
|
Dobos G, De Cevins C, Ly Ka So S, Jean-Louis F, Mathieu S, Ram-Wolff C, Resche-Rigon M, Bensussan A, Bagot M, Michel L. The value of five blood markers in differentiating mycosis fungoides and Sézary syndrome: a validation cohort. Br J Dermatol 2020; 185:405-411. [PMID: 33314029 DOI: 10.1111/bjd.19719] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 11/22/2020] [Accepted: 12/08/2020] [Indexed: 01/12/2023]
Abstract
BACKGROUND Clinical and histological diagnosis of Sézary syndrome (SS) and mycosis fungoides (MF) is challenging in clinical routine. OBJECTIVES We investigated five blood markers previously described for SS (T-plastin, Twist, KIR3DL2, NKp46 and Tox) in a prospective validation cohort of patients. METHODS We included 447 patients in this study and 107 patients were followed up for prognosis. The markers were analysed by reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) on peripheral blood leucocytes and CD4+ T cells in a cohort of consecutive patients with early MF, erythrodermic MF and SS and compared with patients presenting with benign inflammatory dermatoses (BID) and erythrodermic BID. The markers were assessed in parallel to gold standard values such as CD4/CD8 ratio, loss of CD7 and CD26 membrane expression and CD4 absolute values. Sensitivity and specificity were analysed by receiver operator characteristic curves. The prognostic value of selected markers was analysed on a subset of patients. This study was conducted in one centre. RESULTS We defined cut-off values for each marker. T-plastin, Twist and KIR3DL2 had the best validity. SS may be overrepresented. The combination of T-plastin and Twist was able to differentiate between erythrodermic MF or BID and SS. The additional analysis of KIR3DL2 may be useful to predict the prognosis. CONCLUSIONS We propose T-plastin, Twist and KIR3DL2 measured by RT-qPCR as new diagnostic markers for Sézary syndrome.
Collapse
Affiliation(s)
- G Dobos
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - C De Cevins
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - S Ly Ka So
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - F Jean-Louis
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - S Mathieu
- Department of Dermatology, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - C Ram-Wolff
- Department of Dermatology, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - M Resche-Rigon
- SBIM, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - A Bensussan
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - M Bagot
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France.,Department of Dermatology, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - L Michel
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| |
Collapse
|